FY2026 · period end Apr '26 · from the 10-K filed Jun 19, 2026
Data as filed with the SEC, provided for information only — not investment advice.
| Metric | FY26Apr '26 | FY25Apr '25 | FY24Apr '24 | FY23Apr '23 | FY22Apr '22 |
|---|---|---|---|---|---|
| Revenue | $36.36B | $33.54B | $32.36B | $31.23B | $31.69B |
| Gross Profit | $23.64B | $21.91B | $21.15B | $20.51B | $21.54B |
| Operating Income | $6.47B | $5.96B | $5.14B | $5.49B | $5.75B |
| Net Income | $4.80B | $4.66B | $3.68B | $3.76B | $5.04B |
| EPS (Diluted) | $3.73 | $3.61 | $2.76 | $2.82 | $3.73 |
| Metric | FY26Apr '26 | FY25Apr '25 | FY24Apr '24 | FY23Apr '23 | FY22Apr '22 |
|---|---|---|---|---|---|
| Total Assets | $93.03B | $91.68B | $89.98B | $90.95B | $90.98B |
| Total Liabilities | $42.96B | $43.42B | $39.56B | $39.28B | $38.26B |
| Stockholders' Equity | $50.07B | $48.26B | $50.42B | $51.66B | $52.72B |
| Cash & Equivalents | $1.95B | $2.22B | $1.28B | $1.54B | $3.71B |
| Total Debt | $26.17B | $25.64B | $23.93B | $24.34B | $20.37B |
| Metric | FY26Apr '26 | FY25Apr '25 | FY24Apr '24 | FY23Apr '23 | FY22Apr '22 |
|---|---|---|---|---|---|
| Operating Cash Flow | $7.33B | $7.04B | $6.79B | $6.04B | $7.35B |
| Capital Expenditures | $1.90B | $1.86B | $1.59B | $1.46B | $1.37B |
| Free Cash Flow | $5.43B | $5.18B | $5.20B | $4.58B | $5.98B |
| Metric | FY26Apr '26 | FY25Apr '25 | FY24Apr '24 | FY23Apr '23 | FY22Apr '22 |
|---|---|---|---|---|---|
| Gross Margin | 65.0% | 65.3% | 65.3% | 65.7% | 68.0% |
| Operating Margin | 0.2% | 0.2% | 0.2% | 0.2% | 18.2% |
| Net Margin | 0.1% | 0.1% | 0.1% | 0.1% | 15.9% |
| Return on Equity | 9.8% | 9.4% | 7.2% | 7.2% | 9.6% |
| Return on Assets | 5.2% | 5.1% | 4.1% | 4.1% | 5.5% |
| Debt / Equity | 0.52× | 0.53× | 0.47× | 0.47× | 0.39× |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or full history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 10-Q | 0001628280-26-060473 | Jul 31, 2026 | Sep 3, 2026 | Sep 4, 2026 00:18 UTC | EDGAR |
| 10-K | 0001628280-26-044354 | Apr 24, 2026 | Jun 18, 2026 | Jun 19, 2026 00:27 UTC | EDGAR |
| 10-Q | 0001628280-26-011107 | Jan 23, 2026 | Feb 24, 2026 | Feb 25, 2026 02:18 UTC | EDGAR |
| 10-Q | 0001628280-25-053988 | Oct 24, 2025 | Nov 25, 2025 | Nov 26, 2025 02:18 UTC | EDGAR |
| 10-Q | 0001613103-25-000161 | Jul 25, 2025 | Aug 26, 2025 | Aug 27, 2025 01:26 UTC | EDGAR |
| 10-K | 0001613103-25-000091 | Apr 25, 2025 | Jun 20, 2025 | Jun 20, 2025 14:46 UTC | EDGAR |
| 10-Q | 0001613103-25-000022 | Jan 24, 2025 | Feb 25, 2025 | Feb 26, 2025 02:17 UTC | EDGAR |
| 10-Q | 0001613103-24-000165 | Oct 25, 2024 | Nov 26, 2024 | Nov 27, 2024 02:16 UTC | EDGAR |
| 10-Q | 0001613103-24-000147 | Jul 26, 2024 | Aug 27, 2024 | Aug 28, 2024 00:18 UTC | EDGAR |
| 10-K | 0001613103-24-000072 | Apr 26, 2024 | Jun 20, 2024 | Jun 21, 2024 00:16 UTC | EDGAR |
| 10-Q | 0001613103-24-000011 | Jan 26, 2024 | Feb 27, 2024 | Feb 28, 2024 02:16 UTC | EDGAR |
| 10-Q | 0001613103-23-000149 | Oct 27, 2023 | Nov 30, 2023 | Dec 1, 2023 02:16 UTC | EDGAR |
Direct links to SEC EDGAR. MDT has additional filings available on the SEC site.
6 numbers Medtronic plc later changed — same XBRL tag, both filings linked.
INCOME-PRETAX·Q1 1998
Major restatementwas$226.1M
Revised up in a 10-K.
TOTAL-REVENUES·Q1 1998
Major restatementwas$653.2M
Revised up in a 10-K. Any P/S built on the original was 35.6% too high.
NET-INCOME·Q1 1998
Major restatementwas$150.4M
Revised up in a 10-K. Any P/E built on the original was 34.9% too high.
TOTAL-ASSETS·As of Oct 30, 1998
Major restatementwas$3.8B
Revised up in a 10-K.
TOTAL-REVENUES·Q2 1998
Major restatementwas$1.4B
Revised up in a 10-K. Any P/S built on the original was 29.0% too high.
TOTAL-ASSETS·As of Jul 31, 1998
Major restatementwas$2.8B
Revised up in a 10-K.
MDT is not the only one.
See every restatement we've found across the market — or get an alert the next time MDT revises a number.
Restatements are detected by comparing every vintage of a fact across all of Medtronic plc's filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows MDT's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling Medtronic plc — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on MDT yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows on data pinned to its SEC filing. Be the first: run equity_research_brief on MDT and publish the result to your public profile.
Ask about Medtronic plc
Continue in Workspace — cited answers on MDT, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate, with delisted companies kept in.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs